Targets › CFH
2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Mar 2027.
Glycoprotein that plays an essential role in maintaining a well-balanced immune response by modulating complement activation. Acts as a soluble inhibitor of complement, where its binding to self markers such as glycan structures prevents complement activation and amplification on cell surfaces. (UniProt, P08603)
Open in Phaseline: the race on CFH, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Roswell Park Cancer Institute | GT103 anti-CFH monoclonal antibody | CFH | Phase 2 | Advanced Lung Non-Small Cell Carcinoma | Dec 2028 |
| West China Hospital | CFH Protein-loaded Ice Microneedles Complement factor H (CFH) fragment (human, 860-1231aa) delivered intradermally via ice mic | CFH | Phase 1 | Radiation-Induced Skin Fibrosis | Mar 2027 |
Advanced Lung Non-Small Cell Carcinoma (1) Radiation-Induced Skin Fibrosis (1)
antibody (1), protein or peptide (1)
Roswell Park Cancer Institute (1) West China Hospital (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.